DE60103770D1 - Botulinumtoxin zur behandlung endokriner erkrankungen - Google Patents

Botulinumtoxin zur behandlung endokriner erkrankungen

Info

Publication number
DE60103770D1
DE60103770D1 DE60103770T DE60103770T DE60103770D1 DE 60103770 D1 DE60103770 D1 DE 60103770D1 DE 60103770 T DE60103770 T DE 60103770T DE 60103770 T DE60103770 T DE 60103770T DE 60103770 D1 DE60103770 D1 DE 60103770D1
Authority
DE
Germany
Prior art keywords
botulinumtoxin
endocrine diseases
treating endocrine
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60103770T
Other languages
English (en)
Other versions
DE60103770T3 (de
DE60103770T2 (de
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24782116&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60103770(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60103770D1 publication Critical patent/DE60103770D1/de
Application granted granted Critical
Publication of DE60103770T2 publication Critical patent/DE60103770T2/de
Publication of DE60103770T3 publication Critical patent/DE60103770T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60103770T 2000-10-20 2001-08-21 Botulinumtoxin zur behandlung endokriner erkrankungen Expired - Lifetime DE60103770T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/692,811 US6827931B1 (en) 2000-10-20 2000-10-20 Method for treating endocrine disorders
US692811 2000-10-20
PCT/US2001/026123 WO2002034286A1 (en) 2000-10-20 2001-08-21 Methods for treating endocrine disorders

Publications (3)

Publication Number Publication Date
DE60103770D1 true DE60103770D1 (de) 2004-07-15
DE60103770T2 DE60103770T2 (de) 2005-07-07
DE60103770T3 DE60103770T3 (de) 2009-06-25

Family

ID=24782116

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103770T Expired - Lifetime DE60103770T3 (de) 2000-10-20 2001-08-21 Botulinumtoxin zur behandlung endokriner erkrankungen

Country Status (7)

Country Link
US (1) US6827931B1 (de)
EP (1) EP1326631B2 (de)
JP (1) JP2004513895A (de)
AU (1) AU2001285159A1 (de)
DE (1) DE60103770T3 (de)
ES (1) ES2218444T5 (de)
WO (1) WO2002034286A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267008B1 (de) 1999-08-25 2014-07-02 Allergan, Inc. Aktivierbare rekombinante Neurotoxine
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1778279B1 (de) 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmazeutische zusammensetzung mit botulinum neurotoxin a2
DK1776137T3 (en) 2004-08-04 2015-01-05 Ipsen Biopharm Ltd A pharmaceutical composition comprising botulinum neurotoxin A2
WO2006026780A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
AU2005292145C1 (en) * 2004-10-01 2011-07-21 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2662027B1 (de) 2008-05-09 2017-09-27 Holaira, Inc. Systeme, Baugruppen und Verfahren zur Behandlung eines Bronchialbaumes
BRPI0915888E2 (pt) * 2008-06-12 2020-09-01 Syntaxin Ltd polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso
EP3473643A1 (de) * 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusionproteine zur verwendung bei der behandlung von krebs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
EP2161033B1 (de) * 2008-09-09 2013-05-01 Susanne Dr. Grafe Botulinumtoxin zur Erzeugung der zeitweisen Unfruchtbarkeit in einem Wirbeltier (z.B. beim Menschen)
US20120021969A1 (en) * 2009-03-06 2012-01-26 Allergan, Inc. Prosthetic implant shell
CA2779135C (en) 2009-10-27 2018-09-04 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US20140364774A1 (en) * 2013-06-11 2014-12-11 David J. Mishelevich Ultrasound neuromodulation for clinical effects
US20120251573A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
KR20230008892A (ko) * 2013-11-21 2023-01-16 메모리얼 슬로안 케터링 캔서 센터 인간 다능성 줄기 세포로부터 기능적 두개 기원판 유도체의 전문화
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
EP3822286A1 (de) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Kationische neurotoxine
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
US20230381012A1 (en) * 2022-05-31 2023-11-30 Max Azevedo System and Method for Fallopian Birth Control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000042I1 (de) 1993-12-28 2009-01-02 Merz Pharma Gmbh & Co Kgaa Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6272370B1 (en) 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin

Also Published As

Publication number Publication date
EP1326631A1 (de) 2003-07-16
AU2001285159A1 (en) 2002-05-06
EP1326631B2 (de) 2008-10-22
EP1326631B1 (de) 2004-06-09
US6827931B1 (en) 2004-12-07
DE60103770T3 (de) 2009-06-25
ES2218444T5 (es) 2009-04-01
WO2002034286B1 (en) 2002-08-29
WO2002034286A1 (en) 2002-05-02
JP2004513895A (ja) 2004-05-13
DE60103770T2 (de) 2005-07-07
ES2218444T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
DE60103770D1 (de) Botulinumtoxin zur behandlung endokriner erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60117977D1 (de) Vorrichtungen zur behandlung von harninkontinenz
DE60142565D1 (de) Mittel zur wasserbehandlung
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE426373T1 (de) Apparat zur behandlung von zahnen
NO20030241D0 (no) Fremgangsmåte for behandling av multiple brönnintervaller
DE60122242D1 (de) Verfahren zur Bekämpfung von Saatkrankheiten
PT1267650E (pt) Tratamento do tabaco
ATE400283T1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE69921886D1 (de) Methode zur Behandlung vorgefertigter Formteile
DE60120520D1 (de) Verfahren zur behandlung von abwasser
FIU20060389U0 (fi) Luusairauksien hoito
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
NO20032122D0 (no) Forbedret behandling
DE60014928D1 (de) Retinoide zur behandlung von emphysem
DE60101309D1 (de) Diacerein zur behandlung von psoriasis
ATE297914T1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid- derivate zur schmerzbehandlung
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20032789D0 (no) Apparat for lipolyse for estetisk behandling
DE60115647D1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60005566D1 (de) Pyranoindole zur glaukombehandlung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings